Hexaminolevulinate

{{Short description|Optical imaging agent}}

{{cs1 config|name-list-style=vanc|display-authors=6}}

{{UDP|date=June 2019}}

{{More medical citations needed|date=April 2023}}

{{Use dmy dates|date=December 2020}}

{{Infobox drug

| image = Hexaminolevulinate.svg

| width =

| alt =

| caption =

| pronounce =

| tradename = Cysview, Hexvix

| Drugs.com =

| MedlinePlus =

| DailyMedID = Hexaminolevulinate

| pregnancy_AU =

| pregnancy_AU_comment =

| pregnancy_category =

| routes_of_administration =

| class =

| ATC_prefix = V04

| ATC_suffix = CX06

| ATC_supplemental =

| biosimilars =

| legal_AU = S4

| legal_AU_comment = {{cite web | title=Prescription medicines: registration of new chemical entities in Australia, 2016 | website=Therapeutic Goods Administration (TGA) | date=21 June 2022 | url=https://www.tga.gov.au/prescription-medicines-registration-new-chemical-entities-australia-2016 | access-date=10 April 2023}}

| legal_BR =

| legal_BR_comment =

| legal_CA = Rx-only

| legal_CA_comment =

| legal_DE =

| legal_DE_comment =

| legal_NZ =

| legal_NZ_comment =

| legal_UK =

| legal_UK_comment =

| legal_US = Rx-only

| legal_US_comment = {{cite web | title=Cysview- hexaminolevulinate hydrochloride kit | website=DailyMed | date=15 November 2022 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5aeed40d-6841-4adf-8940-f51d439fdfa3 | access-date=10 April 2023}}

| legal_EU =

| legal_EU_comment =

| legal_UN =

| legal_UN_comment =

| legal_status =

| bioavailability =

| protein_bound =

| metabolism =

| metabolites =

| onset =

| elimination_half-life =

| duration_of_action =

| excretion =

| CAS_number = 140898-97-1

| CAS_supplemental =

| PubChem = 6433083

| IUPHAR_ligand =

| DrugBank = DB06261

| ChemSpiderID = 4938272

| UNII = G7H20TKI67

| KEGG = D04436

| ChEBI = 134892

| ChEMBL = 1201784

| NIAID_ChemDB =

| PDB_ligand =

| synonyms =

| IUPAC_name =

| chemical_formula_ref =

| chemical_formula =

| C= | H= | Ag= | Al= | As= | Au= | B= | Bi= | Br= | Ca= | Cl= | Co= | F= | Fe= | Gd= | I=

| K= | Li= | Mg= | Mn= | N= | Na= | O= | P= | Pt= | S= | Sb= | Se= | Sr= | Tc= | Zn= | charge=

| molecular_weight =

| molecular_weight_comment =

| SMILES =

| StdInChI =

| StdInChI_comment =

| StdInChIKey =

| density =

| density_notes =

| melting_point =

| melting_high =

| melting_notes =

| boiling_point =

| boiling_notes =

| solubility =

| sol_units =

| specific_rotation =

}}

Hexaminolevulinate, sold under the brand name Cysview among others, is an imaging agent that lights up under blue light during a blue light cystoscopy. It is used to help detect non-muscle invasive bladder cancer (NMIBC), in particular papillary tumors and carcinoma in situ (CIS).{{cite journal | vauthors = Zhao H, Peng P, Luo Z, Liu H, Sun J, Wang X, Jia Q, Yang Z | title = Comparison of hexaminolevulinate (HAL) -guided versus white light transurethral resection for NMIBC: A systematic review and meta-analysis of randomized controlled trials | journal = Photodiagnosis and Photodynamic Therapy | volume = 41 | issue = | pages = 103220 | date = March 2023 | pmid = 36462704 | doi = 10.1016/j.pdpdt.2022.103220 | url = }}

It made by Photocure ASA, a Norwegian pharmaceutical company.

Hexaminolevulinate is a structural analogue to 5-aminolevulinic acid (a precursor to the porphyrin ring of heme), and is internalized and processed into the photoactive protoporphyrin IX at a high rate by tumor cells. After exposure to 360-450 nm light, the porphyrin will fluoresce red.{{cite web | title = Hexaminolevulinate| url = https://pubchem.ncbi.nlm.nih.gov/compound/Hexaminolevulinate#section=Metabolism-Metabolites | work = PubChem | publisher = U.S. National Library of Medicine }}